Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465904 · ClinicalTrials.gov registry record · NA
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
A NA study of Migraine, sponsored by Cefaly Technology.
- Completed
- Registry status
- NA
- Development phase
- 607
- Enrollment target
- 10
- Study locations
NCT03465904: Completed NA study of Migraine, sponsored by Cefaly Technology.
NCT03465904 is a NA study of Migraine that has completed, run by Cefaly Technology. The registered enrollment target is 607 participants, above the 352-participant average among 102 other Migraine trials with a reported enrollment target (72% higher). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03465904, a NA study of Migraine, has completed, sponsored by Cefaly Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 607 participants
- Enrollment target
- 10
- Study locations
Study Summary
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This randomized, double-blind, sham-controlled trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device.
Primary Outcome
The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the beginning of the e-TNS session.
Conditions Studied
Interventions
- DEVICE Verum Cefaly® Abortive Program device
- DEVICE Sham Cefaly® Abortive Program device
Study Locations (10)
Arizona
- Clinical Research Consortium - Tempe
California
- Pharmacology Research Institute - Encino
Connecticut
- Yale University - New Haven
Florida
- Palm Beach Research Center - West Palm Beach
Georgia
- Meridian Clinical Research (Savannah Neurology) - Savannah
Maryland
- Meridian Clinical Research (Rockville Neurology) - Rockville
Nevada
- Clinical Research Consortium - Las Vegas
New York
- Rochester Clinical Research - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2019-01-11 |
| Phase | NA |
What the finished NCT03465904 record still lists
NCT03465904 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, above the 352-participant average among 102 other Migraine trials with a reported enrollment target (72% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Verum Cefaly® Abortive Program device is the first listed.
NCT03465904 lists 10 locations in 10 states (Arizona, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03465904 about?
NCT03465904 is a clinical study titled "A Phase III Trial of e-TNS for the Acute Treatment of Migraine". The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This randomized, double-blind, sham-controlled trial will study the abortive treatment of migraine using the Cefaly® Abortive Pr...
What is the current status of trial NCT03465904?
This trial is currently completed. It is a NA study. The enrollment target is 607 participants. The study started on 2018-04-10. Estimated completion is 2019-01-11.
What conditions does trial NCT03465904 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03465904?
The interventions under investigation include: Verum Cefaly® Abortive Program device (DEVICE), Sham Cefaly® Abortive Program device (DEVICE).
Who is sponsoring clinical trial NCT03465904?
This trial is sponsored by Cefaly Technology, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03465904 being conducted?
This trial has 10 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03465904's enrollment target sits among peer trials
607 16th of 102 higher than 87 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI